Last reviewed · How we verify
NCT00024479
Studies of the Natural History of Rheumatic Diseases
trial in Rheumatic Diseases in 7,500 participants. Currently enrolling.
Quick facts
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 7,500 |
| Start date | 3 October 2001 |
| Sites | 1 location across United States |
Conditions studied
- Rheumatic Diseases — all drugs for Rheumatic Diseases →
- Arthritis — all drugs for Arthritis →
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Who can join
Adults 18 to 100, any sex, with Rheumatic Diseases or Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will explore the causes of rheumatic diseases and why many of them affect certain minority communities more severely. Rheumatic diseases may cause joint pain, stiffness or swelling. Some can involve bones, muscles, tendons or ligaments. Some cause abnormalities of the immune system-the body s defense against disease. Some rheumatic diseases are painful or deforming and some can be life threatening. Information obtained from this study will be used to learn about the disparities in rheumatic disease in the minority community and to design further, more targeted, research studies to address this issue. Patients with known or suspected rheumatic disease 18 years of age or older may be eligible for this study. Candidates will undergo a medical history and physical examination to confirm the diagnosis of rheumatic disease and determine what is needed for evaluation and treatment. Participants will receive standard medical care for rheumatic disease and arthritis. No experimental treatments, medications or procedures will be included in this study. Procedures may include routine blood tests for blood chemistries, cell counts, and antibodies commonly found in patients with rheumatic disease; a urine test for proteins and cells; and X-rays and other imaging tests to check for abnormalities in the lungs or other organs. All medical information will be kept confidential. Patients who are found to be eligible for other current NIH research studies will be offered an opportunity to participate in these studies....
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A pilot study of yoga as self-care for arthritis in minority communities.
Middleton KR, Ward MM, Haaz S, Velummylum S, et al · · 2013 · cited 16× · PMID 23548052 · DOI 10.1186/1477-7525-11-55 -
Feasibility and assessment of outcome measures for yoga as self-care for minorities with arthritis: a pilot study.
Middleton KR, Ward MM, Haaz Moonaz S, Magaña López M, et al · · 2018 · cited 9× · PMID 29484197 · DOI 10.1186/s40814-018-0248-x
Verify or expand the search:
- PubMed search for NCT00024479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatic Diseases
Currently open trials in the same condition.
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07350395 — Exploring and Measuring the Impact of Steroids in Children and Young People · recruiting
- NCT07278609 — The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions · recruiting
- NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
- NCT06400628 — Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes · NA · recruiting
Other National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) trials
Trials by the same sponsor.
- NCT07012057 — Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis · Phase 2 · withdrawn
- NCT06238531 — A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus · Phase 1 · withdrawn
- NCT05440422 — The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN- · Phase 2 · recruiting
- NCT05738824 — Natural History of Inflammatory Muscle Diseases · recruiting
- NCT05567198 — Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Det · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00024479 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00024479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing